Electra Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $134 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Electra Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).
SEC Form D · Oct 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2025
That is all the official record says: Electra Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Gary S. Koe | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2026) | SEC Form 3 |
| Graham Parry | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2026) | SEC Form 3 |
| Nancy Stagliano | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, director (Form 3, 2026) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, director (Form 3, 2026) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Quehuong (Kathy) Dong | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Quehuong (Kathy) Dong, Pharm.D. | Executive officer | Oct 2025 |
| Beth Seidenberg, M.D. | Director | Oct 2025 |
| Carl Gordon, Ph.D. | Director | Oct 2025 |
| Matthew Fust | Director | Oct 2025 |
| Nancy Stagliano, Ph.D. | Director | Oct 2025 |
| Quehuong (Kathy) Dong, Pharm.D. | Director | Oct 2025 |
| Thomas Geninatti, Ph.D. | Director | Oct 2025 |